Business Context and Reporting Period
This Form 8-K is filed by Cerulean Pharma Inc. (not Dare Bioscience, Inc., as indicated in the metadata request) on March 20, 2017. The filing announces a definitive share purchase agreement with Daré Bioscience, Inc., under which Daré stockholders will become the majority owners of Cerulean. A joint conference call to discuss the transaction was scheduled for March 23, 2017.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity for either company. This report focuses exclusively on the announcement of the proposed transaction and procedural details regarding the solicitation of proxies.
Material Changes
The primary material change is the execution of a definitive share purchase agreement between Cerulean Pharma Inc. and Daré Bioscience, Inc., resulting in a change of control where Daré stockholders will assume majority ownership of Cerulean.
Guidance, Outlook, and Risks
- Outlook: Cerulean intends to file a definitive proxy statement on Schedule 14A with the SEC to seek stockholder approval for the transaction.
- Management Commentary: Investors are urged to read the upcoming Proxy Statement for important information regarding the transaction and the parties involved.
- Risks and Contingencies: The transaction is contingent upon stockholder approval. The filing includes standard disclaimers that this communication does not constitute an offer to sell or buy securities in jurisdictions where such offers would be unlawful.
- Participants: Cerulean, Daré, and their respective directors and executive officers are deemed participants in the solicitation of proxies.
Important Facts for Investor Verification
- Verify the terms of the definitive share purchase agreement in the upcoming Schedule 14A Proxy Statement.
- Confirm the exchange ratio and ownership structure resulting in Daré stockholders becoming majority owners of Cerulean.
- Review the interests of directors and executive officers in the proposed transaction as detailed in the Proxy Statement.
- Note that the registrant in this filing is Cerulean Pharma Inc., not Dare Bioscience, Inc.